Roche, Hookipa Pharma agree $25 million deal for arenaviral immunotherapy

Roche, Hookipa Pharma agree $25 million deal for arenaviral immunotherapy

Submitted by admin on October 21, 2022 - 10:18am
Source: 
Pharmaphorum
News Tags: 
Roche
Hookipa
KRAS mutation
arenaviral
HB-700
Headline: 
Roche, Hookipa Pharma agree $25 million deal for arenaviral immunotherapy
snippet: 

Swiss pharma giant Roche has moved to strengthen its position in the KRAS-mutated cancer space through a $25 million licensing and collaboration agreement with Austrian arenaviral technology firm Hookipa Pharma.

Do Not Allow Advertisers to Use My Personal information